As a provider of monitoring and validation systems for regulated environments, Vaisala regulatory experts are often asked to help troubleshoot issues in pharmaceutical and medical device supply chains. In this article we answer three questions we often receive on how to perform mapping studies for regulated environments.
Recognising the critical role that emerging biopharmaceutical companies play in the global marketplace, Quintiles today expanded its solution set with the launch of the Quintiles Emerging Biopharma Solution – a new offering designed to meet the unique clinical development needs and goals of these companies.
For the second year in a row, Quintiles has been named the CRO industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) report, CRO Quality Benchmarking Phase I Service Providers (2014). In this year’s survey, Quintiles was recognized as the “overwhelming leader” when survey respondents were asked to identify CROs they consider leaders in the Phase I space. This announcement follows Quintiles’ recognition, also for the second year in a row, as the industry leader that best differentiates itself on service quality for Phase II/III research in an earlier ISR report released in April.
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research’s (ISR) 2014 CRO Quality Benchmarking Phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year’s report, Quintiles is the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
$332.0 million of service revenue in the first quarter; 10% constant currency service revenue growth compared to the first quarter of 2014.
PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London. This is the second year in a row that PRA has won this prestigious award. PRA also swept the Clinical Team of the Year category. PRA winners include:
PRA Health Sciences (PRA), a leading global clinical research organization, is expanding its business in Swansea with the creation of 87 new jobs. The expansion will be supported by £990,060 of business finance from the Welsh Government enabling PRA to grow its local workforce to 280 by December 2017.
In immediate response to the devastating earthquake that left Nepal in ruins on April 25th, SHL quickly reached out to World Vision to hold an internal donation event at its key manufacturing sites in Taiwan where a booth is being set up for staff to contribute in any amount possible. SHL employees at regional offices in Sweden, USA and China have also all joined in the company’s efforts through World Vision International or their respective channels.
SHL will be attending and exhibiting at the upcoming Guide for Prefilled Syringe Seminar 2015 in Tokyo, Japan, where Executive Director of Business Development Thomas Schönknecht has been invited to speak on the topic of "Insight Into the Changing World of Auto Injectors: Trends, Partnerships and Key Learnings."
To enhance the user experience of our corporate website and to better support our group companies including SHL Medical, SHL Healthcare, SHL Technologies and SHL Pharma, SHL Group is proud to introduce our newest corporate website.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.